ClinicalTrials.gg
Not yet recruitingNCT06526624Updated Jul 30, 2024

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

A Phase 3 interventional study of HS-20093 in Limited-stage Small-cell Lung Cancer, sponsored by Hansoh BioMedical R&D Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.

Read the detailed description

This is a randomized, controlled, open-label, multi-center, phase III clinical study to evaluate the efficacy and safety of HS-20093 versus active surveillance as consolidation therapy in participants with limited-stage small cell lung cancer (LS-SCLC) who have not progressed after receiving chemoradiotherapy (CRT).

This study consists of an experimental arm and a control arm. The experimental arm will be administered HS-20093, and the control arm will only receive active surveillance. Efficacy and safety were assessed in both arms by follow-up analyses.

02

Conditions studied

  • Limited-stage Small-cell Lung Cancer
03

In context

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

This study's planned enrollment of 406 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.

Browse Small Cell Lung Carcinoma studies →

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have signed Form.
  2. Males or females ≥18 years old.
  3. Patients with limited-stage SCLC who are deemed unsuitable for surgery or decline surgery.
  4. performance status of 0-1.
  5. Patients who have received CRT and have not progressed.
  6. Minimum > 12 weeks.
  7. Males or Females should be using adequate measures throughout the study.
  8. Females must not be pregnant at screening or have evidence of non-.

Exclusion criteria

Exclusion Criteria:

  1. Patients with mixed SCLC or NSCLC or sarcoma-like carcinoma, or large cell neuroendocrine carcinoma.
  2. Patients with extensive-stage SCLC.
  3. Disease progression during CRT or before randomization.
  4. Received or are receiving the following treatments:

    1. For LS-SCLC, prior treatment with or current use of other chemotherapy regimens other than platinum plus etoposide
    2. Received any other anti-cancer treatment.
    3. Previous or current treatment with B7-H3 target therapy.
    4. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study drug.
    5. Major surgery within 4 weeks prior to the first dose of study drug.
  5. Interstitial lung disease (ILD)/non-infectious pneumonitis.
  6. History of other primary .
  7. Inadequate bone marrow reserve or organ functions.
  8. Severe, uncontrolled or active cardiovascular disorders.
  9. Severe or uncontrolled diabetes.
  10. Serious or poorly controlled hypertension.
  11. Severe bleeding symptoms or bleeding tendencies within 1 month prior to randomization.
  12. Severe arteriovenous thrombosis occurred within 3 months prior to randomization.
  13. Serious infection within 4 weeks prior to randomization.
  14. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
  15. Having serious neurological or mental disorders.
  16. History of to any component of HS-200093 or its similar drugs.
  17. Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
406 participants (estimated)

Study arms

  • Experimental
    HS-20093

    Patients with LS-SCLC who have not progressed following CRT. Patients in this arm will be administrated HS-20093 intravenously at a dose of 8.0 mg/kg, Q3W continuously until disease progression or until other criteria for discontinuation of treatment are met.

    Drug: HS-20093

  • No intervention
    Active surveillance

    Patients with LS-SCLC who have not progressed following CRT. Patients in this arm will receive active surveillance until disease progression or until other criteria for discontinuation of active surveillance are met.

Interventions

  • Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) According to RECIST v1.1 by Independent Review Committee (IRC)

    To assess the efficacy of HS-20093 vs active surveillance in terms of PFS. PFS is defined as the time from randomization until the date of objective disease progression or death, whichever occurred first, based on IRC using RECIST v1.1.

    Time frame: Approximately 6 years

  2. Overall survival (OS)

    To assess the efficacy of HS-20093 vs active surveillance in terms of OS. Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

    Time frame: Approximately 6 years

Secondary outcomes

  1. PFS at 12 Months (PFS12) or 18 Months (PFS18) According to RECIST v1.1 by IRC

    PFS12 and PFS18 are defined as the progression-free survival at 12 months and 18 months from the date of randomization, respectively, based on IRC using RECIST v1.1.

    Time frame: Approximately 6 years.

  2. ORR According to RECIST v1.1 by IRC

    ORR is defined as the percentage of participants with BOR of CR or PR per RECIST v1.1

    Time frame: From the date of randomization until the date of disease progression or withdrawal from study, up to approximately 6 years.

  3. DCR According to RECIST v1.1 by IRC

    DCR is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease)

    Time frame: From the date of randomization until the date of disease progression or withdrawal from study, approximately 6 years.

  4. DoR by IRC

    DoR only applies to participants whose best overall response is CR or PR. The start date is the date of first documented response of CR or PR, and the end date is defined as the date of the first documented progression or death due to underlying disease.

    Time frame: From the date of CR, PR until the date of disease progression or death, approximately 6 years.

  5. PFS According to RECIST v1.1 by investigators (INVs)

    PFS is defined as the time from randomization until the date of objective disease progression or death, whichever occurred first, based on INVs using RECIST v1.1

    Time frame: Approximately 6 years.

  6. PFS12 or PFS18 According to RECIST v1.1 by INVs

    PFS12 and PFS18 are defined as the progression-free survival at 12 months and 18 months from the date of randomization, respectively, based on INVs using RECIST v1.1.

    Time frame: Approximately 6 years.

  7. ORR According to RECIST v1.1 by INVs

    ORR is defined as the percentage of participants with BOR of CR or PR per RECIST v1.1 by INVs.

    Time frame: From the randomization until the date of disease progression or withdrawal from study, up to approximately 6 years.

  8. DCR According to RECIST v1.1 by INVs

    DCR is defined as the percentage of patients who have a best overall response (CR, PR, or stable disease).

    Time frame: From the randomization until the date of disease progression or withdrawal from study, up to approximately 6 years.

  9. DoR According to RECIST v1.1 by INVs

    DoR is defined as the percentage of patients who have a best overall response (CR, PR, or stable disease).

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, up to approximately 6 years.

  10. Proportion of patients alive at 24 months (OS24) or 36 months (OS36)

    OS24 and OS36 are defined as the proportion of patients alive at 24 months and 36 months from the date of randomization, respectively, based on INVs using RECIST v1.1.

    Time frame: Approximately 6 years.

  11. Incidence and severity of treatment-emergent adverse events

    Adverse event (assessed according to NCI CTCAE v5.0) is defined as any untoward medical occurrence in a participant without regard to possibility of causal relationship.

    Time frame: From the date of first dose until 90 days after the final dose. A cycle is 21 days.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Nov 2027, 38 months later.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 38 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartEst.
Sep 30, 2024
Primary completionEst.
Nov 30, 2027
CompletionEst.
Jan 31, 2029
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06526624
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Sep 30, 2024 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Jul 30, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion